Shopping Cart

Your shopping cart is currently empty

IRL-1620 acetate

Name: IRL-1620 acetate
Brand: TargetMol
SKU: T15595L
Price: 113 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T15595L

Alias IRL-1620 acetate(142569-99-1 free base)

IRL-1620 acetate is an effective and selective agonist of Endothelin B receptor (ETB) with a Ki of 16 pM which is more selective than ETA with a Ki of 19 μM.

IRL-1620 acetate

😃Good

Purity: 96.64%

Catalog No. T15595LAlias IRL-1620 acetate(142569-99-1 free base)

IRL-1620 acetate is an effective and selective agonist of Endothelin B receptor (ETB) with a Ki of 16 pM which is more selective than ETA with a Ki of 19 μM.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$113	-	In Stock
5 mg	$281	-	In Stock
10 mg	$412	-	In Stock
25 mg	$648	-	In Stock
50 mg	$870	-	In Stock
100 mg	$1,170	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:96.64%

Resource Download

COA HPLC MS

Product Introduction

Bioactivity

Description	IRL-1620 acetate is an effective and selective agonist of Endothelin B receptor (ETB) with a Ki of 16 pM which is more selective than ETA with a Ki of 19 μM.
Targets&IC50	ETB receptor:16 pM(Ki), ETA receptor:19 μM(Ki)
In vitro	IRL-1620 acetate is 60 times more selective for the ETB receptor than ET-3 (KiETA/ KiETB=1900)[3].
In vivo	IRL-1620 acetate improves both acquisition (learning) and retention (memory) on the water maze task and enhances angiogenic and neurogenic remodeling. Rats treated with IRL-1620 acetate significantly reduces the cognitive impairment induced by Aβ. IRL-1620 acetate treatment enhances the number of blood vessels labeled with VEGF compared to vehicle treatment[1]. IRL-1620 acetate, restores analgesic tolerance to morphine and oxycodone, but it does not affect morphine and oxycodone induced decrease in NGF/PI3K expression. IRL-1620 acetate attenuates opioid tolerance without the involvement of NGF/PI3K pathway[2]. IRL-1620 acetate (1-100 nM) induces contractions of the guinea pig trachea. The effective concentration that produces 30 % of 60 mM KCI-induced contraction is estimated to be 28 nM for IRL 1620[3]. IRL-1620 acetate (1-100 nM) increases cytosolic Ca2+ in the vascular endothelium ([Ca]E) with little effect on resting muscle tone, and relaxes the norepinephrine-stimulated tone with an increase in [Ca]E, in rat aorta[3].
Synonyms	IRL-1620 acetate(142569-99-1 free base)

Chemical Properties

Molecular Weight	1881
Formula	C₈₈H₁₂₁N₁₇O₂₉
Smiles	CC(O)=O.O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC([C@H]([C@@H](C)CC)NC([C@H]([C@@H](C)CC)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC3=CNC=N3)NC([C@H](C)NC([C@H](CC4=CC=CC=C4)NC([C@H](CC5=CC=C(O)C=C5)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC(CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Relative Density.	no data available
Sequence	Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp
Sequence Short	DEEAVYFAHLDIIW

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc